TETRA Technologies enters the final week of September with a striking divergence: options traders are more defensively positioned than at any point in the past year, even as the stock's borrow market remains loose and short sellers face no meaningful squeeze pressure.
The options signal is the sharpest data point this week. The put/call ratio has jumped to 1.03 — a 52-week high — against a 20-day average of just 0.46. That's nearly three standard deviations above the norm, a z-score of 2.99, and the move happened almost overnight: the PCR ran below 0.41 through mid-September before spiking on September 21-22. Demand for downside protection has rarely been this elevated relative to TTI's own recent baseline, and it follows a stock that has already fallen 9% on the week and 16% over the past month to close at $6.02.
Short interest tells a more textured story. Bears have been adding gradually — SI has climbed to 7.6% of the free float, up roughly 6% on the week and 12% over the past month. The official FINRA settlement figure puts days-to-cover at 5.1, which is worth noting but not alarming. What keeps this from reading as a crowded short is the lending environment: borrow availability is running at 714%, well within normal territory, meaning shares are easy to find and there is no mechanical squeeze pressure building. Cost to borrow has actually eased over the past month to 0.42%, close to its lowest level since August. The ORTEX short score, at 50.8, sits squarely in neutral territory. Shorts are rebuilding, but the setup is measured rather than aggressive.
The Street remains constructive on paper, though with less conviction than before. Stifel's Stephen Gengaro, one of the stock's most consistent bulls, trimmed his price target from $13 to $12 this morning while keeping his Buy rating — the clearest recent signal that even the friendly end of the analyst community is marking down its near-term expectations. The consensus mean target across the coverage group is $11.63, implying roughly 93% upside from the current price. That gap between target and price reflects a bull case built on management's ambitious 2030 guidance — revenue growing at a 25%-plus CAGR to a $430-460 million range, with EBITDA up 180% to roughly $325 million at the midpoint. The bear case centres on oil and gas cyclicality: a sustained move lower in natural gas prices would directly pressure demand for TTI's completion fluids and water management services. Forward earnings revisions have actually been strong — the 12-month forward EPS growth factor ranks in the 90th percentile — but that hasn't translated into price support. The EV/EBITDA multiple has drifted up modestly to 8.4x over the past month, while price-to-book has compressed to 2.2x, down nearly 0.3 turns over 30 days.
One institutional data point stands out in the ownership register. Pictet Asset Management filed a Schedule 13D on TTI in April 2025, disclosing a 5.3% stake — the 13D classification signals activist intent rather than a passive position. Pictet's filing predates the current selloff by over a year, and stakes are as-last-disclosed around the 5% threshold, so the actual position size may have changed without a subsequent filing. Still, an activist on the register is a background variable worth tracking. BlackRock has been adding shares, reporting 8.3% ownership as of August 31, up modestly from the prior period. Needham Investment Management and Cramer Rosenthal McGlynn both made substantial additions through the June quarter, though those disclosures reflect prices meaningfully above current levels.
The next scheduled earnings date is November 3. The last three quarterly prints produced one-day moves of +8%, +13%, and +5%, with five-day follow-throughs in the 12-17% range — all to the upside. With the put/call ratio at a 52-week high and the stock down 35% year-to-date, how that earnings setup develops between now and early November is the clearest near-term watch point.
See the live data behind this article on ORTEX.
Open TTI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
